Two drugs walked into a cardiology conference. One walked out vindicated. One walked out with a question mark. That is the most honest summary of what happened at ACC 2026 in New Orleans last week, where prevention finally got top billing at one of medicine's largest conferences, with more than 16,000 attendees, and where prevention trials occupied primetime slots as the evidence delivered two completely different verdicts on what actually moves the needle.
The vindicated drug is evolocumab, a PCSK9 inhibitor sold by Amgen. A subgroup analysis of the VESALIUS-CV trial presented at the conference showed that evolocumab reduced major adverse cardiovascular events by 31 percent in patients who had diabetes but no known significant atherosclerosis, meaning they had never had a heart attack or been diagnosed with blockages, yet sat in a risk category that cardiologists had historically treated with statins and surveillance rather than aggressive intervention. At 96 weeks, patients on evolocumab drove their LDL cholesterol down to a median of 44 milligrams per deciliter, compared with 105 for the placebo group, in a cohort of 3,655 participants with a median age of 65 followed for a median of 4.8 years. According to the ACC press release, Dr. Nicholas Marston of Brigham and Women's Hospital and Harvard Medical School said: "We don't have to wait until someone has atherosclerosis to treat them intensively. We can — and should — be much more proactive."
That is a clean verdict. Cut LDL hard and early, and people who have never had a cardiac event but carry elevated risk, particularly those with diabetes, see real benefit. The trial was not a fluke; VESALIUS-CV was a pre-specified subgroup with a biologically coherent mechanism. LDL causes atherosclerosis; lowering LDL prevents it. This is the oldest story in preventive cardiology, and it just got sharper.
The drug that walked out with a question mark is olezarsen, an RNA interference therapeutic developed by Ionis Pharmaceuticals that targets APOC3, a gene involved in triglyceride metabolism. Olezarsen is approved for familial chylomicronemia syndrome, a rare genetic condition in which the body cannot break down dietary fats, resulting in dangerously elevated triglycerides, and it slashed triglycerides by 60 percent in a CCTA sub-study presented at ACC. It also reduced apolipoprotein B by 15 percent. These are not small effects. But at 12 months, there was no measurable impact on non-calcified coronary plaque volume — the direct anatomical readout cardiologists actually want to see improve. The sub-study enrolled 468 participants with a median age of 63, over half with diabetes, median baseline triglycerides of 249 mg/dL. As Marston noted, per Medical XPress, an outcomes trial would be needed before anyone could claim that lowering triglycerides in this way prevents heart attacks.
The distance between dramatically lowering a biomarker and preventing disease is where drug development goes to die. Olezarsen has the approval, the mechanism, and the trial data. It does not yet have the verdict.
What connects these two stories, beyond the fact that they shared a conference and a presenter, is that they represent the two main paths pharma has been chasing in preventive cardiology for the past decade. One path is LDL. It has been validated so many times by so many drug classes that it has become the field's bedrock. Statins work because they lower LDL. Ezetimibe works because it lowers LDL. PCSK9 inhibitors work because they lower LDL. The biology is tight, the outcomes data is voluminous, and the 2026 ACC/AHA dyslipidemia guidelines released last month recommend LDL-C treatment targets of less than 55 mg/dL for very high-risk patients, less than 70 mg/dL for high-risk individuals, and less than 100 mg/dL for primary prevention — targets that a decade ago would have sounded aggressive to the point of clinical radicalism.
The other path is triglycerides. Specifically, triglyceride-rich remnant particles, which are believed to contribute to atherosclerosis through a mechanism that partially overlaps with LDL but is not identical. The logic goes that triglycerides, particularly in the form of very-low-density lipoproteins, are an independent driver of cardiovascular risk, and that lowering them should produce benefits similar to what LDL reduction delivers. Several large trials have tested this hypothesis. Several have failed. The field keeps trying.
Olezarsen's plaque imaging data does not disprove the triglyceride hypothesis. A 12-month CCTA study is not an outcomes trial. But it does not confirm it either, and in a field that has been burned before, "does not confirm" is often treated as failure. Marston's own call for an outcomes trial is the most honest thing anyone said about it.
The third drug in the room, and the one that has cardiologists most divided on what to make of it, is obicetrapib, a CETP inhibitor from NewAmsterdam Pharma. CETP inhibitors have a history in this field that can be described charitably as turbulent. Four previous attempts by other companies all failed or were abandoned, some after large trials showed harm. Obicetrapib is the fifth entry, and it is the first to come forward with both a phase 3 LDL reduction signal and a genuinely ongoing outcomes trial. In the BROADWAY phase 3 trial, obicetrapib reduced LDL-C by 33 percent at day 84 compared with placebo. The PREVAIL cardiovascular outcomes trial enrolled over 9,000 patients and is expected to produce topline data at the end of 2026. If it is positive, obicetrapib becomes the first successful CETP inhibitor in history and opens a mechanism the field abandoned prematurely. If it is negative, this is the fifth funeral for the same hypothesis.
What makes obicetrapib additionally interesting, and this is something the cardiology world is beginning to notice, is that it showed effects on Alzheimer's disease biomarkers in the BROADWAY trial data. In pre-specified analyses announced in June 2025, obicetrapib treatment led to statistically significant reductions in plasma biomarkers of Alzheimer's pathology in both the full study population and in ApoE4 carriers over 12 months. These are subgroup analyses in a cardiovascular trial, not a neurology study, and they require substantial caveats. But the direction is consistent with a growing body of literature suggesting that lipid metabolism and neurodegeneration are more connected than the specialties have historically acknowledged. NewAmsterdam has licensed European commercialization rights to the Menarini Group.
The broader structural shift driving all of this is the new PREVENT-ASCVD risk calculator, which replaces the older Pooled Cohort Equations in the 2026 ACC/AHA guidelines and is among the most consequential updates in the document. PREVENT estimates 10-year and 30-year cardiovascular risk, a distinction the previous tool did not make, and its lower LDL-C targets reach back decades earlier than prior recommendations. The guidelines also recommend measuring lipoprotein(a) at least once in all adults, a Class I recommendation that reflects a generation of genetics research showing Lp(a) as an independent, inherited risk factor that statin therapy does not meaningfully address. These are not minor housekeeping changes. They represent a field that has decided, at the guideline level, that prevention is no longer the periphery of the conference. It is the main event.
That reorientation has a policy tailwind. The Make America Healthy Again Commission released a strategy in September 2025 with more than 120 initiatives aimed at chronic disease prevention, and industry booths at ACC 2026 reflected the shift: they advertised PCSK9 inhibitors, renal denervation therapies, and increasingly sophisticated cardiac CT scans pitched as the future of prevention rather than diagnosis.
None of this resolves the fundamental open question: what happens when an outcomes trial for obicetrapib reads out at the end of 2026? If it is positive, the LDL pathway gets a new chapter and the CETP graveyard gets a resurrection. If it is negative, the fifth attempt at this mechanism closes the book. Either way, the olezarsen question — does triglyceride lowering prevent disease or only numbers on a lab report? — remains open, unanswered, and worth the outcomes trial Marston himself is asking for. The conference gave the field two verdicts. One was clear. The other is still pending.
† Add footnote: "Source-reported; not independently verified."
†† Add footnote: "Source-reported; not independently verified." Or attribute to a specific source (e.g., "according to the MAHA Commission" or cite the relevant source document).
† Add footnote: "Source-reported; not independently verified."
†† Add footnote: "Source-reported; not independently verified." Or attribute to a specific source (e.g., "according to the MAHA Commission" or cite the relevant source document).
